Join Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21
Nexalin Technology (NASDAQ: NXL) will present an investor webinar on April 21, 2026 at 4:15 p.m. ET hosted by RedChip Companies.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nexalin Technology (NASDAQ: NXL) will present an investor webinar on April 21, 2026 at 4:15 p.m. ET hosted by RedChip Companies. CEO Mark White will review Nexalin's non-invasive Deep Intracranial Frequency Stimulation (DIFS™) clinical evidence, Gen-3 HALO Clarity headset, Virtual Clinic platform, international regulatory clearances, and U.S. clinical and regulatory initiatives, followed by a live Q&A. Registration is free via RedChip.
Details
News Market Reaction – NXL
On Apr 14, the day this news came out, NXL closed 0.28% below the previous close.
Data tracked by StockTitan Argus for the Apr 14 session.
Key Figures
- Q3 2025 revenue
- $18,149
- Quarterly revenue, down from $36,031 in Q3 2024
- Q3 2025 net loss
- $2,276,311
- Quarterly net loss reported in Q3 2025 10-Q
- Nine-month net loss
- $5,845,635
- Net loss for first nine months of 2025
- Cash balance
- $590,075
- Cash and cash equivalents as of Q3 2025
- Short-term investments
- $3,762,602
- Short-term investments reported in Q3 2025 10-Q
- Public offering proceeds
- $5,317,000
- Gross proceeds from May/June 2025 equity offering
- ATM capacity
- $10,000,000
- Maximum aggregate offering price under amended ATM program
- Shares outstanding
- 18,189,606 shares
- Shares outstanding as of Sept 30, 2025 in 424B5
Historical Context
-
Peer-reviewed pilot showed DIFS reduced depression and self-injury scores.
-
Announced pivotal HALO Clarity insomnia trial to support de novo FDA filing.
-
Highlighted Congressional support for neurostimulation research and VA/NIH alignment.
-
Launched NeuroCare AI virtual clinic integrated with Gen-3 HALO headset.
-
Summarized peer-reviewed neuroimaging backing DIFS as non-invasive brain stimulation.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
deep intracranial frequency stimulation medical
neurostimulation medical
virtual clinic technical
ai-enabled technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
ORLANDO, FL, April 14, 2026 (GLOBE NEWSWIRE) -- RedChip Companies will host an investor webinar on April 21, 2026, at 4:15 p.m. ET with Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW).
The exclusive event will feature Nexalin’s CEO Mark White, who will provide an in-depth overview of the company’s differentiated approach to mental healthcare through its proprietary, non-invasive Deep Intracranial Frequency Stimulation (DIFS™) technology. White will highlight Nexalin’s expanding body of clinical evidence—including peer-reviewed studies and collaborations with leading institutions such as UC San Diego—while outlining progress across its next-generation product portfolio, including the Gen-3 HALO™ Clarity headset and integrated Virtual Clinic platform designed to enable scalable, physician-supervised, at-home treatment. With multiple international regulatory clearances in place and U.S. clinical and regulatory initiatives advancing, Nexalin is executing a clear pathway toward global commercialization. The presentation will also detail how Nexalin’s patented technology, real-time AI-enabled patient monitoring, and growing international footprint position the Company to capitalize on the rapidly expanding mental health and neurostimulation markets.
A live question and answer session will follow the presentation.
To register for the free webinar, please visit: https://www.redchip.com/webinar/NXL/87033006926
Questions can be pre-submitted to NXL@redchip.com or online during the live event.
About Nexalin Technology, Inc.
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin's products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, Oman and Israel. Additional information about the Company is available at: https://nexalin.com/.
About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. Founded in 1992 as a small-cap research firm, RedChip gained early recognition for initiating coverage on emerging blue chip companies such as Apple, Starbucks, Daktronics, Winnebago, and Nike. Over the past 34 years, RedChip has evolved into a full-service investor relations and media firm, delivering concrete, measurable results for its clients, which have included U.S. Steel, Perfumania, Cidara Therapeutics, and Celsius Holdings, among others. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
Sign Up for RedChat
RedChat™ is an AI-powered investment research assistant designed to give investors instant access to critical insights from SEC filings, press releases, and corporate disclosures. Built to streamline small-cap and microcap stock research, RedChat analyzes thousands of public company documents and delivers clear, context-rich answers to investor questions in seconds. Instead of manually reviewing lengthy filings, investors can simply ask RedChat about financial results, partnerships, business strategy, or recent announcements and receive precise, source-based summaries. Investors can experience RedChat and start exploring stocks today at www.redchip.com/stocks or www.red.chat.
To learn more about RedChip's products and services, please visit: https://www.redchip.com/corporate/investor_relations.
"Discovering Tomorrow's Blue Chips Today"™
Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/
Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies
Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/
Follow RedChip on Twitter: https://twitter.com/RedChip
Follow RedChip on YouTube: https://www.youtube.com/@redchip
Follow RedChip on Rumble: https://rumble.com/c/c-3068340
Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest
Contact:
Dave Gentry
RedChip Companies Inc.
1-407-644-4256 | 1-800-REDCHIP (733-2447)
NXL@redchip.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.